Detailed Narrative
FY26: A Year of Transition and De-risking
FY26 was characterized as a 'bridge year' for Bharat Parenterals, focusing on regulatory clearances, subsidiary expansion, and capacity building. Consolidated revenue remained broadly flat at INR 345.4 crores compared to INR 340 crores last year. However, the company achieved significant de-risking in its business mix, leading to a 485% expansion in consolidated EBITDA to INR 15.8 crores from INR 2.7 crores in the previous year. This improvement was largely driven by Innoxel's performance, which narrowed its EBITDA loss by INR 23.5 crores.
Innoxel Lifesciences Achieves EBITDA Positivity and Regulatory Milestones
Innoxel Lifesciences, the complex generics subsidiary, was a key growth driver, with revenue surging by 174.1% to INR 72.4 crores in FY26 from INR 26.4 crores. Crucially, Innoxel turned EBITDA positive for the first time in Q4 FY26, reporting INR 1.4 crores. The company secured US FDA establishment inspection report clearance and FAMHP (Belgian regulator) EUGMP clearance with zero critical observations, positioning it for commercial supply to the US and European markets from FY27. Innoxel signed 23 deals during the year, including 7 out-licensing and 16 CMO-CDO partnerships.
Varenyam Healthcare Turns Profitable with Strong Domestic Growth
Varenyam Healthcare, the branded domestic business, achieved profitability in FY26, with revenue growing by 13.7% to INR 58.4 crores from INR 51.4 crores last year. It reported an EBITDA of INR 2.5 crores, a significant turnaround from a loss of INR 3 crores in the prior year. The productivity per medical representative per month (PCPM) grew by 31% year-on-year to over 3.85 lakhs, and corporate hospital coverage expanded to over 7,500 institutions across 26 states. The company plans to expand its field force to over 250 people and launch 7 new products, including Remishot, and a new gynecology division in FY27.
Standalone Business Faces Headwinds, Focuses on Upgrades
The standalone business (BPL) experienced a 23% decline in revenue to INR 234 crores in FY26 from INR 304 crores last year. This was attributed to deferred export tenders, a strategic decision to exit low-margin volume businesses, and production line upgrades. Despite the revenue decline, the standalone business maintained a 9% EBITDA margin (INR 21 crores) and a 6.8% PAT margin (INR 16 crores), while reducing finance costs by 28%. The order book stands at INR 171 crores, providing reasonable visibility for FY27, with growth expected from Southeast Asia, Africa, and MENA regions.
Varenyam Biolifesciences: Long-Term Project with Revised Timelines
Varenyam Biolifesciences, a complex injectable platform targeting emerging regulated markets, remains under construction with an approved budget of INR 160 crores and CWIP of INR 33 crores at year-end. Civil works are 50% complete, and equipment procurement is 40% complete. The commissioning of the facility is now targeted for September 2027, with line validation by March 2028. The first regulatory filing under EUGMP is expected in Q1 FY29, and commercial supply in Q4 FY29, a revision from earlier FY27 timelines due to geopolitical disturbances.
FY27 Outlook: Commercial Inflection Across All Businesses
Management expects FY27 to be a year of commercial inflection. The standalone business is guided for 10-15% revenue growth with 10-15% EBITDA margins. Innoxel is projected to achieve 35-45% revenue growth and 20-25% EBITDA margins, with first commercial CMO supply starting in Q2 FY27 and 10 new filings. Varenyam Healthcare is expected to grow revenue by 20-25% with 8-13% EBITDA margins, driven by field force expansion and new product launches. The company aims for a full recovery of standalone business to FY25 numbers by FY28, and peak revenue of INR 400-500 crores in 3-4 years.